Celldex Therapeutics (CLDX) Return on Sales (2016 - 2025)
Historic Return on Sales for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to 86.36%.
- Celldex Therapeutics' Return on Sales fell 731600.0% to 86.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.36%, marking a year-over-year decrease of 709100.0%. This contributed to the annual value of 22.49% for FY2024, which is 19400.0% down from last year.
- According to the latest figures from Q3 2025, Celldex Therapeutics' Return on Sales is 86.36%, which was down 731600.0% from 77.53% recorded in Q2 2025.
- Celldex Therapeutics' Return on Sales' 5-year high stood at 3.84% during Q2 2021, with a 5-year trough of 220.88% in Q2 2022.
- Over the past 5 years, Celldex Therapeutics' median Return on Sales value was 60.32% (recorded in 2021), while the average stood at 71.4%.
- In the last 5 years, Celldex Therapeutics' Return on Sales plummeted by -2170400bps in 2022 and then soared by 1329000bps in 2025.
- Over the past 5 years, Celldex Therapeutics' Return on Sales (Quarter) stood at 60.32% in 2021, then soared by 73bps to 16.42% in 2022, then skyrocketed by 36bps to 10.48% in 2023, then crashed by -282bps to 40.08% in 2024, then tumbled by -115bps to 86.36% in 2025.
- Its Return on Sales was 86.36% in Q3 2025, compared to 77.53% in Q2 2025 and 77.4% in Q1 2025.